The relationship between the myocardial T2* value and left ventricular volumetric and functional parameters in thalassemia major patients.

PURPOSE Cardiac involvement in thalassemia major (TM) is mainly characterized by left ventricular dysfunction caused by iron overload. Cardiovascular magnetic resonance imaging (MRI) including myocardial T2* measurement is becoming increasingly popular for quantitatively evaluating myocardial iron overload. The aim of this study was to evaluate the relationship between the myocardial T2* value and left ventricular functional parameters and to examine the associations between the degree of cardiac iron load and various clinical parameters. MATERIALS AND METHODS A retrospective analysis of 47 patients (25 males and 22 females; mean age, 23.0±5.4 years) with TM was performed. Myocardial iron load was assessed by T2* measurements, and volumetric functions were analyzed using the steady state free precession sequence. RESULTS In patients with myocardial iron deposition (T2* < 20 ms), the mean left ventricular ejection fraction (LVEF) was 64.73±4.94%. The LVEF of patients with myocardial siderosis was significantly lower than that of patients without myocardial siderosis (r=0.35, P = 0.014). Inverse and significant correlations between both the left ventricular (LV) end-systolic volume index and the LV end-diastolic volume index and the myocardial T2* value (r=-0.32, P = 0.027 and r=-0.29, P = 0.046, respectively) were observed. There was an inverse correlation between the myocardial T2* value and the liver iron concentration (r=-0.31, P = 0.037). Cardiac T2* was not associated with serum ferritin levels, pre-transfusion hemoglobin levels or the annual red cell consumption rate. CONCLUSION Myocardial iron load assessed by cardiac MRI (T2*) is associated with deterioration in left ventricular function. Thalassemia major patients with myocardial siderosis may have LVEF values within normal limits, but this result must be interpreted cautiously.

[1]  D. Pennell,et al.  Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron. , 2005 .

[2]  J. M. Walker The heart in thalassaemia. , 2002, European heart journal.

[3]  V. Positano,et al.  Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients , 2010, Magnetic resonance in medicine.

[4]  D. Pennell T2* Magnetic Resonance and Myocardial Iron in Thalassemia , 2005, Annals of the New York Academy of Sciences.

[5]  M. Cappellini,et al.  Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.

[6]  E. Gotsis,et al.  Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. , 2007, Haematologica.

[7]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[8]  N. Olivieri The beta-thalassemias. , 1999, The New England journal of medicine.

[9]  E. Eracleous,et al.  Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2* , 2006, Hemoglobin.

[10]  Thomas D. Coates,et al.  Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.

[11]  D. Pennell,et al.  Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. , 2003, European heart journal.

[12]  B. Akpınar,et al.  Dual-echo TFE MRI for the assessment of myocardial iron overload in beta-thalassemia major patients. , 2010, Diagnostic and interventional radiology.

[13]  T. S. St. Pierre,et al.  Measurement and Mapping of Liver Iron Concentrations Using Magnetic Resonance Imaging , 2005, Annals of the New York Academy of Sciences.

[14]  J. Wood,et al.  Diagnosis and management of transfusion iron overload: The role of imaging , 2007, American journal of hematology.

[15]  D. Pennell,et al.  Journal of Cardiovascular Magnetic Resonance Open Access Combined Chelation Therapy in Thalassemia Major for the Treatment of Severe Myocardial Siderosis with Left Ventricular Dysfunction , 2008 .

[16]  G. Link,et al.  Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.

[17]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[18]  D. Farmakis,et al.  Cardiac status in well‐treated patients with thalassemia major , 2004, European journal of haematology.

[19]  S. Colan,et al.  Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. , 2008, JACC. Cardiovascular imaging.

[20]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[21]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[22]  D J Pennell,et al.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major , 2009, Circulation.

[23]  D. Alehan,et al.  The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance , 2010, The International Journal of Cardiovascular Imaging.

[24]  D. Canatan,et al.  Hemoglobinopathy Control Program in Turkey , 2006, Public Health Genomics.

[25]  D. Pennell,et al.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[26]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[27]  R. Moats,et al.  Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia , 2005, Annals of the New York Academy of Sciences.

[28]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[29]  M. Tsironi,et al.  Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. , 2005, Chest.